eShowcase: PHT eSense Sensors
Tools for Clinical Trials Professionals
Wireless technology takes the worry out of inaccurate patient reported outcomes
PHT Corporation (Charlestown, MA) has created a new device that employs wireless technology to measure physiological measurements such as peak expiratory flow or blood sugar levels wirelessly, then integrates the data with an eDiary. The technology also enables subjects to send subjective data such as pain level versus activity level. With eSense, they can wear a small device to record data during the day, then return home and transmit the information to an eDiary that night. The advantage, says PHT, is that clinical trial subjects no longer have to remember scores or times, or worry about transcription errors.
The technology that makes eSense possible is a low-power wireless design that allows devices within 10 feet of each other to communicate. This also enables eSense to be integrated into tiny, wearable devices that are more convenient. Subjects simply use the device near their eDiary and the data transmits automatically, with date and time stamps for every reading.
PHT eSense Sensors
PHT Corporation, (617) 973-1600, www.phtcorp.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
